{
    "name": "methenamine/sodium acid phosphate",
    "comment": "Rx",
    "other_names": [
        "Uroquid-Acid No. 2",
        "Utac"
    ],
    "classes": [
        "Antibiotics",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/uroquid-acid-no-2-utac-methenamine-sodium-acid-phosphate-999453",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: methenamine is excreted in human milk; caution advised, risk to infant cannot be ruled out"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: methenamine is excreted in human milk; caution advised, risk to infant cannot be ruled out"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Sodium acid phosphate ",
                    "description": [
                        "Rare reports of acute phosphate nephropathy with oral sodium phosphate products used for colon cleansing before colonoscopy",
                        "Some cases have resulted in permanent renal function impairment requiring long-term hemodialysis",
                        "Risk factors for acute phosphate nephropathy include age >55 yr, hypovolemia, baseline kidney disease, bowel obstruction, active colitis, and those using medicines that affect renal perfusion or function (eg, diuretics, ACE inhibitors, ARBs, NSAIDs)",
                        "Carefully follow dosing regimen as recommended (pm/am split dose) with adequate hydration"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sodium phosphate rectal",
            "description": {
                "common": "sodium phosphate rectal, sodium acid phosphate.\nEither increases effects of the other by pharmacodynamic synergism. Contraindicated. Either increases toxicity of the other. Coadministration of various sodium phosphate preparations are known to cause electrolyte disturbances and hypovolemia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide, methenamine. Other (see comment). Contraindicated. \nComment: This combination may form an insoluble precipitate in the urine, decreasing the effects of both agents."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "baloxavir marboxil",
            "description": {
                "common": "sodium acid phosphate will decrease the level or effect of baloxavir marboxil by  cation binding in GI tract. Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "methenamine, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "microbiota oral",
            "description": {
                "common": "methenamine decreases effects of microbiota oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Microbiota oral contains bacterial spores. Antibacterial agents may decrease efficacy if coadministered. Complete antibiotic regimens 2-4 days before initiating microbiota oral. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "potassium phosphates, IV",
            "description": {
                "common": "sodium acid phosphate and potassium phosphates, IV both increase  serum potassium. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sulfadiazine",
            "description": {
                "common": "methenamine, sulfadiazine. Other (see comment). Contraindicated. \nComment: This combination may form an insoluble precipitate in the urine, decreasing the effects of both agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "sodium acid phosphate and deflazacort both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine",
            "description": {
                "common": "sodium acid phosphate decreases levels of dextroamphetamine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisdexamfetamine",
            "description": {
                "common": "sodium acid phosphate decreases levels of lisdexamfetamine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methamphetamine",
            "description": {
                "common": "sodium acid phosphate decreases levels of methamphetamine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylenedioxymethamphetamine",
            "description": {
                "common": "sodium acid phosphate decreases levels of methylenedioxymethamphetamine by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omadacycline",
            "description": {
                "common": "sodium acid phosphate will decrease the level or effect of omadacycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pseudoephedrine",
            "description": {
                "common": "methenamine decreases effects of pseudoephedrine by unknown mechanism. Use Caution/Monitor. Urinary excretion of indirect acting alpha/beta agonists (eg, pseudoephedrine) may increase when administered concomitantly with urinary acidifying agents, resulting in lower serum concentrations."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sarecycline",
            "description": {
                "common": "sodium acid phosphate will decrease the level or effect of sarecycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium picosulfate/magnesium oxide/anhydrous citric acid",
            "description": {
                "common": "methenamine decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Dysuria",
            "percent": null
        },
        {
            "name": "Gastric upset",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Stomach pain",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        }
    ]
}